Goldman Sachs resumed coverage of Revolution Medicines with a Buy rating and a $267 price target. The call signals a positive outlook on the oncology-focused biotech's pipeline.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
